FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials
• Childhood cancers1 trial
• Kidney cancer1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 36 trials

Status

• Completed4 trials
• Active, not recruiting1 trial
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche3 trials
• Daiichi Sankyo1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• OBI Pharma, Inc1 trial

Running trials

• Active, not recruiting

  Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

  NCT03562637· Phase 3· OBI Pharma, Inc· Source

Closed trials

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Hoffmann-La Roche· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

  NCT03194893· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source